Where there’s a will, there’s a way. Patients are our will.
Status – Pivotal Phase 2/3 study began enrollment 4Q19; Filing initiation began December 2020 under U.S. FDA Real-Time Oncology Review pilot program
Study Sponsor – Cardiff University (for AML18, AML19)
For Vyxeos® (daunorubicin and cytarabine) full Prescribing Information, including Boxed WARNING, please visit www.jazzpharma.com/medicines/our-medicines
Study Sponsor – MD Anderson Cancer Center
For Defitelio® full Prescribing Information, please visit www.jazzpharma.com/medicines/our-medicines.
This page is for U.S. residents only. By clicking on this page, you confirm you are a U.S. resident.
Thank you for visiting JazzPharma.com. The site you are about to visit is maintained by a third party who is solely responsible for its content; Jazz Pharmaceuticals is not responsible for the content or privacy practices of any third-party websites. Click Cancel to return or OK to continue.